Global Immune Thrombocytopenia Market, By Type (Acute, Chronic), Treatment (Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins and Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Immune Thrombocytopenia Market Analysis and Size
The global immune thrombocytopenia market is expected to witness significant growth during the forecast period. Fast approvals from regulatory bodies such as the Food and Drug Administration (FDA) will impact the growth of the immune thrombocytopenia market. Major market players in the immune thrombocytopenia market also focus on expansion activities to promise seamless distribution. Autoimmune diseases, medications, pregnancy, chronic infections, and certain cancers are common secondary triggers of this disease. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global immune thrombocytopenia market in the forecast period 2022-2029. The expected CAGR of global immune thrombocytopenia market is tend to be around 1.04% in the mentioned forecast period. The market was valued at USD 3.08 billion in 2021, and it would grow upto USD 3.35 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Immune Thrombocytopenia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute, Chronic), Treatment (Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins and Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Hepalink Group. (China), Teva Pharmaceutical Industries Ltd. (Israel), Amarillo Biosciences, inc (U.S.), Bolder Bio Technology, Inc. (U.S.), GENOSCO Inc (U.S.), Hansa Biopharma (Sweden), Janssen Pharmaceuticals, Inc (Belgium), Eisai Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Market Definition
Immune thrombocytopenia is a type of rare haematological bleeding disorders that is characterised by abnormally low level of blood platelet that results in the uncontrolled blood loss and wound. It is usually found in young women and in immunocompromised patients. A low platelet count causes extreme bleeding, which causes many symptoms of immune thrombocytopenia. In extreme cases, recurrent bleeding episodes can lead to anemia, which can induce fatigue and impede reaction to exertion. Severe bleeding into the brain can happen in rare situations. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Global Immune Thrombocytopenia Market Dynamics
Drivers
- Increasing Mergers and Acqusitions
The growing number of merger and acquisitions have resulted in a significant market growth rate. For instance, in 2018, Dova Pharmaceuticals declared a collaboration with Shanghai Fosun Pharmaceuticals to develop and distribute Doptelet in China and Hong Kong. Likewise, Novartis declared the acquisition of oncology and pipeline department of Glaxo Smith Kline plc. The aim is to extend its business across the world and establish a wider customer reach. This boost the market growth.
- Involvement of Multiple Strategies by Market Players
Different strategies adopted by major market players are expected to enhance the market in the region. For instance, Swedish Orphan Biovitrum AB (Sobi) acquired U.S.-based Dova Pharmaceuticals. This acquisition allowed Sobi to expand its product portfolio in hematology and support the commercial presence in the U.S.. This movements are helping in boosting the market growth.
Opportunities
- Rising Drug Approvals
Pharmaceutical companies that are operating in the rare diseases arena have received approvals from the FDA in the last few years. For instance, in April 2018, Rigel Pharmaceuticals, Inc. got an approval for fostamatinib disodium hexahydrate tablets from the U.S. FDA for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia. Furthermore, the European Medicines Agency (EMEA) recognized chronic immune thrombocytopenia as an orphan disease, with approximately 50,000 adult patients with chronic immune thrombocytopenia in the European Union.
- Increasing Awareness About Blood Related Disorders
Rise in awareness about blood-related disorders and government initiatives for improving health care access in highly developing countries are projected to create significant opportunities in the global market.
Restraints/Challenges
- Lack of knowledge in emerging markets
Lack of knowledge among the developing market players create a huge restraint in the market. Proper awareness and understanding is necessary for the flourishing business of the market. Several awareness programs should be conducted to increase the market growth and thus, in return will eliminate the hindrance.
- High Cost of Treatment
The treatment involved in this disease such as Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins, are a bit high-end. It requires huge expenditure. This factor hamper the growth of the market.
This global immune thrombocytopenia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global immune thrombocytopenia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Immune Thrombocytopenia Market
The COVID-19 pandemic has produced blockages in drug pipelines and supply chain activities in the health care sector. For market players, this has put unparalleled budget pressure on their expenditure. On the other hand, numerous medicinal regimens are being followed to cope with the rising pandemic. Multiple efforts have been made worldwide to provide a dependable and effective treatment for COVID-19. Manufacturing and the supply chains were stopped, resulting in losses to manufacturers, dealers, and consumers. Currently, the market is deteriorating; though, in the pre-pandemic era, as the condition improves, the demand is estimated to rise due to growing health concerns.
Recent Developments
- In January 2021, Sobi (Swedish Orphan Biovitrum AB) declared the European Commission (EC) approval for Doptelet which is used for the treatment of primary chronic immune thrombocytopenia in adult patients.
- Grifols SA decided to purchase GC Pharma Group's plasma fractionation and purification facilities in Montreal, along with 11 plasma collection centers in the U.S., in July 2020.
Global Immune Thrombocytopenia Market Scope
The global immune thrombocytopenia market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acute
- Chronic
Treatment
- Thrombopoietin Receptor Agonists
- Romiplostim
- Eltrombopag
- Avatrombopag
- Lusutrombopag
- Corticosteroids
- Aristocort.
- Bubbli-Pred
- Celestone
- Intravenous Immunoglobulins
- Abaloparatide
- Nintedanib
- Risankizumab
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Immune Thrombocytopenia Market Regional Analysis/Insights
The global immune thrombocytopenia market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global immune thrombocytopenia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare expenditure, increased patient awareness, and the high prevalence of bleeding disorders.
Asia-Pacific dominates the market due to large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Immune Thrombocytopenia Market Share Analysis
The global immune thrombocytopenia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global immune thrombocytopenia market.
Key players operating in the g global immune thrombocytopenia market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Hepalink Group. (China)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amarillo Biosciences, inc (U.S.)
- Bolder Bio Technology, Inc. (U.S.)
- GENOSCO Inc (U.S.)
- Hansa Biopharma (Sweden)
- Janssen Pharmaceuticals, Inc (Belgium)
- Eisai Co., Ltd (Japan)
SKU-